At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
18F-DCFPyLdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 14, 2015·Updated Jan 31, 2020
In Brief
A clinical study evaluating 18F-DCFPyL for Adenocarcinoma of the Prostate. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedAug 2015
Primary CompletionNov 2016
Study CompletionMar 2019
TodayJul 2026
First PostedAug 14, 2015
Enrollment StartJun 2, 2015
Primary CompletionNov 4, 2016
Study CompletionMar 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.9 years ago
Interventions
18F-DCFPyLdrug
18F-DCFPyL PET/CT